Neulasta

(Pegfilgrastim)

Phase 3Protein / enzyme

Pegfilgrastim is used to help prevent serious infections in cancer patients undergoing chemotherapy by boosting the body's production of white blood cells, which fight infections.[1] Neulasta is currently being investigated across 16 indications[3], with its most advanced program in Phase 3.[1]

Neulasta is one of 423 small molecule programs targeting Coronary Artery Disease. It is currently in Phase 3.

Indications

206

Total Trials

Active Trials

422

Competitors

Pipeline

Status by Indication[3][1]

Indication

Coronary Artery DiseaseActive, not recruiting

Aplastic AnemiaRecruiting

LymphomaCompleted

Esophageal AdenocarcinomaNot yet recruiting

Hematopoietic and Lymphoid Cell NeoplasmActive, not recruiting

Lung AdenocarcinomaActive, not recruiting

Breast CancerCompleted

Ovarian CancerTerminated

Diffuse Large B-Cell LymphomaUnknown status

Multiple MyelomaRecruiting

Coronary Artery DiseasePreclinical

Active, not recruiting

Aplastic AnemiaPhase 2

Recruiting

LymphomaPhase 3

Completed

Esophageal AdenocarcinomaPhase 2

Not yet recruiting

Hematopoietic and Lymphoid Cell NeoplasmPreclinical

Active, not recruiting

Lung AdenocarcinomaPhase 2

Active, not recruiting

Breast CancerPhase 3

Completed

Ovarian CancerPhase 3

Terminated

Diffuse Large B-Cell LymphomaPhase 3

Unknown status

Multiple MyelomaPhase 3

Recruiting

Showing 10 of 16 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Neulasta

Amgen

Phase 3

45 2

Zolymbus

AbbVie

Preclinical

1 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Spravato

WWim Janssens

Preclinical

2 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Acupan

YYonsei University

Preclinical

1 10

Chantix

PPrism Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Recruiting

Multiple Myeloma

NCT06520176

Phase 3Active, not recruiting

Mediastinal Large B-Cell Lymphoma

NCT04759586

Q1 2027

Phase 3Active, not recruiting

Breast Cancer

NCT00070564

Phase 2Active, not recruiting

Diffuse Large B-Cell Lymphoma

NCT03943901

Phase 2Active, not recruiting

Lung Adenocarcinoma

NCT00334815

Phase 2Active, not recruiting

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

NCT03147612

Clinical

Trials by Indication[1]

Breast Cancer44 trials

SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT02643420·406 enrolled

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00124111

Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00080626·19 enrolled

Show 41 more trials

A Study of LY2523355 in Participants With Breast Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01416389·39 enrolled

Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer

Active, not recruiting·CCentre Leon Berard·Phase 2·NCT03571633·90 enrolled

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT02953340·237 enrolled

Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00107510·58 enrolled

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Completed· Amgen logo

Amgen·Phase 2·NCT00115414

Treatment for Elderly Patients With High Risk Breast Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT00117910

Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer

Unknown status·AAnglo Celtic Cooperative Oncology Group·Phase 4·NCT00030758·816 enrolled

AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer

Completed·NNational Cancer Institute (NCI)·N/A·NCT00310089·33 enrolled

Epirubicin in Treating Women Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Completed·—·Phase 2·NCT00253500·15 enrolled

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

Completed· Amgen logo

Amgen·Phase 3·NCT00035594·928 enrolled

Bevacizumab, Doxorubicin, and Cyclophosphamide Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients Who Have Undergone Surgery for Early-Stage Breast Cancer

Unknown status·MMemorial Sloan Kettering Cancer Center·N/A·NCT00436709·75 enrolled

Doxorubicin or Epirubicin and Cyclophosphamide in Treating Older Women With Invasive Breast Cancer

Unknown status·—·Phase 3·NCT00516425·1,000 enrolled

Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer

Active, not recruiting·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT00433420·2,000 enrolled

Epirubicin, Docetaxel, and Pegfilgrastim in Treating Women With Locally Advanced or Inflammatory Breast Cancer

Completed·NNCIC Clinical Trials Group·Phase 1/2·NCT00066443·93 enrolled

Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Completed· Teva logo

Teva·Phase 2/3·NCT00837265·334 enrolled

Pegfilgrastim and Darbepoetin Alfa in Support of Adjuvant Chemotherapy for Breast Cancer

Completed·—·Phase 2·NCT00146562·135 enrolled

A Randomized, Multicenter Pragmatic Trial Comparing Bone Pain From a Single Dose of Pegfilgrastim to 5 Doses of Daily Filgrastim in Breast Cancer Patients Receiving Neoadjuvant/Adjuvant Chemotherapy

Completed·OOttawa Hospital Research Institute·Phase 4·NCT04781959·233 enrolled

LCI-BRE-MTN-NIR-001:Ph I Study of Niraparib in Combo With Standard Chemo in Metastatic Trip Neg Breast Cancer

Withdrawn·WWake Forest University Health Sciences·Phase 1·NCT04762901

Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer

Terminated·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT03329378·7 enrolled

A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer

Completed·NNSABP Foundation Inc·Phase 3·NCT00887536·1,613 enrolled

Temperature-Sensitive Liposomal Doxorubicin and Hyperthermia in Treating Women With Locally Recurrent Breast Cancer

Terminated·—·Phase 1·NCT00346229·29 enrolled

Neugranin in Breast Cancer Participants Receiving Doxorubicin/Docetaxel

Completed· Teva logo

Teva·Phase 3·NCT01126190·381 enrolled

Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer

Active, not recruiting·UUniversity of Kansas Medical Center·Phase 2·NCT03639948·120 enrolled

Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

Unknown status·IInstitute of Cancer Research, United Kingdom·Phase 3·NCT00301925·4,400 enrolled

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00394251·197 enrolled

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00119262·226 enrolled

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00856492·215 enrolled

Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer

Completed·UUniversity of Wisconsin, Madison·Phase 2·NCT03301350·29 enrolled

Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients

Completed·YYonsei University·Phase 2·NCT03575520·63 enrolled

Phase 2 Study of SPI-2012 or Pegfilgrastim for the Management of Neutropenia in Participants With Breast Cancer

Completed· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 2·NCT01724866·148 enrolled

Paclitaxel With Trastuzumab and Lapatinib in HER2-Positive Early Stage Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01827163·20 enrolled

A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03197935·333 enrolled

Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer

Terminated·UUniversity of Nebraska·Phase 2·NCT00679029·15 enrolled

Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients

Completed·NNanogen Pharmaceutical Biotechnology Joint Stock Company·Phase 1·NCT03376503·24 enrolled

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

Terminated·NNational Cancer Institute (NCI)·Phase 1/2·NCT00063934·31 enrolled

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Completed·TThe Methodist Hospital Research Institute·Phase 1/2·NCT02834403·37 enrolled

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy

Completed·—·Phase 2·NCT01847001·10 enrolled

Trial of Eribulin Followed by Doxorubicin & Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

Terminated·EEmory University·Phase 2·NCT01498588·7 enrolled

Reduced Dose of Pegfilgrastim as Support for Chemotherapy for Breast Cancer

Completed·—·Phase 3·NCT05283616·122 enrolled

Phase 2 Neoadjuvant Doxorubicin and Cyclophosphamide -> Docetaxel With Lapatinib in Stage II/III Her2Neu+ Breast Cancer

Completed·GGeorge Albert Fisher·Phase 2·NCT00404066·21 enrolled

Phase III Trial of Continuous Schedule AC + G vs. Q 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer

Active, not recruiting·SSWOG Cancer Research Network·Phase 3·NCT00070564·3,294 enrolled

Lymphoma28 trials

Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma

Completed· Amgen logo

Amgen·Phase 2·NCT00115193·77 enrolled

IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma

Completed·—·Phase 1·NCT01491841·33 enrolled

Rituximab and Combination Chemotherapy in Treating Older Patients With Previously Untreated B-Cell Lymphoma

Completed·UUnknown Sponsor·Phase 2·NCT00290667·586 enrolled

Show 25 more trials

Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma

Completed·OOHSU Knight Cancer Institute·Phase 2·NCT00074178·22 enrolled

Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP

Terminated·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 1/2·NCT02983097·34 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed AIDS-Related B-Cell Non-Hodgkin's Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00389818·43 enrolled

Pegfilgrastim and Combination Chemotherapy With or Without Rituximab in Treating Older Patients With Aggressive B-Cell Non-Hodgkin Lymphoma

Completed·UUniversität des Saarlandes·Phase 2·NCT00726700·109 enrolled

Treatment for Subjects With Non-Hodgkin's Lymphoma

Completed· Amgen logo

Amgen·Phase 2·NCT00117897

Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00118209·524 enrolled

Pegfilgrastim vs. Filgrastim - Comparison of Mobilized Blood Stem Cells in Patients With Non Hodgkin-lymphoma

Completed·UUniversity Hospital Tuebingen·Phase 2·NCT00306111·14 enrolled

Fludeoxyglucose F 18-PET/CT Imaging in Assessing Response to Chemotherapy in Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Hodgkin Lymphoma

Completed·UUniversity College, London·Phase 3·NCT00678327·1,202 enrolled

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT01840566·17 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma

Unknown status·CCancer Research UK·Phase 2·NCT00974792·150 enrolled

A Study of Peripheral Blood Progenitor Cell (PBPC) Mobilisation by Chemotherapy With Pegfilgrastim or Filgrastim in Subjects With Non-Hodgkin's Lymphoma

Completed· Amgen logo

Amgen·Phase 2·NCT00117455

Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00086944·25 enrolled

A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.

Unknown status·TThe Alvin and Lois Lapidus Cancer Institute·Phase 2·NCT00333008·27 enrolled

Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00217503·15 enrolled

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

Completed·MMayo Clinic·Phase 1/2·NCT00670358·138 enrolled

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00392834·34 enrolled

Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas

Not yet recruiting·—·Phase 1·NCT07278856·20 enrolled

An Expanded Access Program of Pegfilgrastim (Neulastim) in Participants With Non-Hodgkin's Lymphoma (NHL)

Completed· Roche logo

Roche·Phase 4·NCT02782845·53 enrolled

Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT01169636·62 enrolled

Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas

Completed·WWashington University School of Medicine·Phase 1·NCT02181218·24 enrolled

Pegfilgrastim on Day +3 Compared to Day +1 After Salvage Chemotherapy for Patients With Refractory or Relapsed Aggressive Lymphoma

Unknown status·RRabin Medical Center·Phase 3·NCT02238873·300 enrolled

Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial

Completed·IInstitut Bergonié·Phase 2·NCT00911183·67 enrolled

Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL)

Terminated·RRush University Medical Center·Phase 2·NCT02531308·5 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Patients With Stage III or Stage IV Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00049595·552 enrolled

A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT03220022·46 enrolled

Diffuse Large B-Cell Lymphoma6 trials

Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00101010·80 enrolled

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Unknown status·FFondazione Italiana Linfomi - ETS·Phase 3·NCT00499018·399 enrolled

Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma

Active, not recruiting·MMayo Clinic·Phase 1·NCT04323956·50 enrolled

Show 3 more trials

Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Lymphoma

Completed·—·Phase 1/2·NCT02073097·48 enrolled

Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma

Terminated·UUniversity of Washington·Phase 1·NCT04156828·12 enrolled

A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT03943901·27 enrolled

Chemotherapy6 trials

Various G-CSF Regimens to Prevent Infection During Chemotherapy

Completed·AAcademisch Ziekenhuis Maastricht·Phase 3·NCT00536081·172 enrolled

Pegfilgrastim as Support to Pediatric Sarcoma Patients Receiving Chemotherapy

Completed· Amgen logo

Amgen·Phase 2·NCT00035620·44 enrolled

Pharmacokinetics and Pharmacodynamics Study of Pegfilgrastim in Chemotherapy Patients

Unknown status·HHangzhou Jiuyuan Gene Engineering Co. Ltd.,·Phase 1·NCT01637493·24 enrolled

Show 3 more trials

Combination Chemotherapy and Filgrastim or Pegfilgrastim in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Completed·GGynecologic Oncology Group·Phase 2·NCT00031629·51 enrolled

Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy

Completed·—·Phase 2·NCT00410696·80 enrolled

Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Completed·CChildren's Oncology Group·Phase 3·NCT00304070·78 enrolled

Multiple Myeloma5 trials

Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients

Recruiting·—·Phase 3·NCT06520176·99 enrolled

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma

Unknown status·EErasme University Hospital·Phase 2·NCT00526734·100 enrolled

Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma

Completed·MMichaela Liedtke·Phase 1/2·NCT01355705·14 enrolled

Show 2 more trials

Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00067639·50 enrolled

Pharmacokinetic (PK)-Directed Dosing of Captisol Enabled Melphalan for Patients With Multiple Myeloma or Light Chain (AL) Amyloidosis Undergoing High Dose Therapy and Autologous Hematopoietic Progenitor Cell Transplant

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT02909036·46 enrolled

80 more indications

Acute Lymphoblastic Leukemia5 trials

Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT03518112·6 enrolled

Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01256398·66 enrolled

Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00671658·220 enrolled

Show 2 more trials

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1/2·NCT05032183·4 enrolled

Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01319981·31 enrolled

Neutropenia4 trials

Colony-Stimulating Factors to Relieve Neutropenia in Patients With Recurrent Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 2·NCT00004192·60 enrolled

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Unknown status·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT03294577·221 enrolled

Plinabulin iv Solution in Prevention of TAC Induced Neutropenia

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 2·NCT04227990·115 enrolled

Show 1 more trial

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

Completed· Teva logo

Teva·Phase 3·NCT02044276·101 enrolled

Germ Cell Tumor4 trials

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00470366·60 enrolled

Combination Chemotherapy and Pegfilgrastim in Treating Men With Metastatic Germ Cell Tumors

Completed·—·Phase 2·NCT00453232·20 enrolled

High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01172912·47 enrolled

Show 1 more trial

Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors

Unknown status·UUniversity of Southampton·Phase 1/2·NCT00551122·23 enrolled

Non-Small Cell Lung Cancer4 trials

Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer

Terminated· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00113386·19 enrolled

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT01557959·45 enrolled

Dose-Dense Induction/Neoadjuvant Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer

Terminated·—·Phase 2·NCT02157116·13 enrolled

Show 1 more trial

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00077311·160 enrolled

Endometrial Cancer3 trials

Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer

Completed·GGOG Foundation·Phase 3·NCT00063999·1,381 enrolled

Intraperitoneal Paclitaxel, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Stage III-IV Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00575952·27 enrolled

Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

Completed·GGynecologic Oncology Group·Phase 3·NCT00006011·659 enrolled

Mantle Cell Lymphoma3 trials

Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT00787969·74 enrolled

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00433537·77 enrolled

Bendamustine and Rituximab Alternating With Cytarabine and Rituximab for Untreated Mantle Cell Lymphoma

Completed·WWashington University School of Medicine·Phase 1·NCT02728531·18 enrolled

Leukemia3 trials

Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00278161·94 enrolled

Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

Completed·MM.D. Anderson Cancer Center·Phase 1/2·NCT00472849·92 enrolled

Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05645718·27 enrolled

Uterine Leiomyosarcoma2 trials

Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery

Terminated·GGynecologic Oncology Group·Phase 3·NCT01533207·38 enrolled

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

Completed·GGynecologic Oncology Group·Phase 2·NCT00101127

Advanced Cancer2 trials

A Study for Participants With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01214629·54 enrolled

A Dose-Escalation Study for Patients With Advanced Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 1·NCT01214642·63 enrolled

Chronic Lymphocytic Leukemia2 trials

Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·MMayo Clinic·Phase 2·NCT00816595·68 enrolled

Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00546377·50 enrolled

Soft Tissue Sarcoma2 trials

PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma

Completed·MMasonic Cancer Center, University of Minnesota·N/A·NCT00346125·70 enrolled

Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00061984·455 enrolled

Fallopian Tube Cancer2 trials

Docetaxel, Trabectedin, and G-CSF or Pegfilgrastim in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00569673·71 enrolled

Erlotinib, Docetaxel, and Carboplatin in Treating Patients With Newly Diagnosed Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00217529

Ovarian Cancer2 trials

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Terminated·SSutro Biopharma, Inc.·Phase 2/3·NCT05870748·600 enrolled

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Recruiting·TTORL Biotherapeutics, LLC·Phase 2·NCT06690775·230 enrolled

Small Cell Lung Cancer2 trials

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00554463·5 enrolled

A Trial of Amrubicin and Carboplatin With Pegfilgrastim in Patients With Extensive-Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01076504·81 enrolled

Bladder Cancer2 trials

Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer

Completed·UUniversity of Washington·Phase 2·NCT04383743·17 enrolled

Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00478361·40 enrolled

Patients With Solid Tumors2 trials

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 3

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 3·NCT03102606·105 enrolled

Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2

Completed·BBeyondSpring Pharmaceuticals Inc.·Phase 2·NCT04345900·55 enrolled

Immunogenicity2 trials

Comparative Immunogenicity Study Comparing TPI-120 to Neulasta® in Healthy Adult Subjects

Completed·AAdello Biologics, LLC·Phase 1·NCT03202927·102 enrolled

Assessing the Immunogenicity of 2 Subcutaneous Doses of CHS-1701 (Coherus Pegfilgrastim) With 2 Subcutaneous Doses Neulasta®

Completed·CCoherus Oncology, Inc.·Phase 1·NCT02418104·303 enrolled

Stem Cell2 trials

Pegfilgrastim for Stem Cell Mobilization in Children (Meg-5)

Unknown status·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT00751894·30 enrolled

Evaluation of Pegfilgrastim for Stem Cell Mobilization in Children

Terminated·UUniversity Hospital, Clermont-Ferrand·Phase 2·NCT00695370·30 enrolled

Esophageal Adenocarcinoma1 trial

Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma

Not yet recruiting·—·Phase 2·NCT07059611·34 enrolled

Stem Cell Transplantation1 trial

Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation

Terminated·CCentre Leon Berard·N/A·NCT01541072·34 enrolled

Locally Advanced Head and Neck Cancer1 trial

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT00352118·4 enrolled

Coronary Artery Disease1 trial

Peg-Granulocyte-Colony Stimulating Factor (GCSF) for Coronary Collateral Growth in Coronary Artery Disease Patients

Completed·IInsel Gruppe AG, University Hospital Bern·N/A·NCT00886509·50 enrolled

Squamous Cell Carcinoma1 trial

A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01059643·103 enrolled

Trial1 trial

CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

Completed·CCancer Trials Ireland·Phase 2·NCT00812669·52 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies

Completed·WWashington University School of Medicine·Phase 2·NCT02369458·48 enrolled

Cervical Cancer1 trial

Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01266447·27 enrolled

Metastatic Colon Cancer1 trial

Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00094809·252 enrolled

Rhabdomyosarcoma1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Metastatic Rhabdomyosarcoma or Sarcoma

Completed·CChildren's Oncology Group·Phase 2·NCT00003955·77 enrolled

Efficacy1 trial

Efficacy of Generic Pegfilgrastim vs Brand Name Pegfilrastim for Neutrophil Recovery After Autotransplant

Completed·HHospital Universitario Dr. Jose E. Gonzalez·Phase 2·NCT05338047·30 enrolled

Follicular Lymphoma1 trial

Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Completed·RRoswell Park Cancer Institute·Phase 2·NCT01682044·20 enrolled

Relapsed or Refractory1 trial

Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Recruiting·—·Phase 1/2·NCT06709495·63 enrolled

Advanced Sarcoma1 trial

Study of Vorinostat in Combination With Gemcitabine and Docetaxel in Advanced Sarcoma

Completed·UUnknown Sponsor·Phase 1/2·NCT01879085·37 enrolled

Temozolomide1 trial

Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT02943733·18 enrolled

Gastroesophageal Junction1 trial

Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00069953·43 enrolled

Thyroid Cancer1 trial

Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer

Terminated·—·Phase 1/2·NCT00077103·4 enrolled

Carboplatin1 trial

A Study of Carboplatin/Paclitaxel With Pegfilgrastim Supported by Haematopoietic Progenitor Cell Re-Infusion in Whole Blood

Completed· Amgen logo

Amgen·Phase 2·NCT00117442·61 enrolled

Bone pain1 trial

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT02392039·1 enrolled

Ewing's Sarcoma1 trial

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Terminated·SStanford University·Phase 2·NCT01313884·3 enrolled

Chondrosarcoma1 trial

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00073983·54 enrolled

PRP1 trial

Comparison of Quality and Quantity of M-PRP Cellular Content Filgrastim vs. Pegfilgrastim

Completed·AAndrews Research & Education Foundation··NCT05573386·15 enrolled

Induction Therapy1 trial

Treatment of PTCL With Aggressive Induction Therapy Followed by Autologous SCT Using Denileukin Diftitox (Ontak)

Terminated·UUniversity of California, San Francisco·Phase 2·NCT00632827·21 enrolled

Treatment1 trial

Dose Finding Study of KRN125 (Pegfilgrastim) for Treatment of Neutropenic Patients

Completed· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 2·NCT00364468·107 enrolled

Advanced or Metastatic Solid Tumors1 trial

Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01654965·17 enrolled

Growth1 trial

PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study

Completed· Amgen logo

Amgen·Phase 3·NCT00911170·847 enrolled

Relapse1 trial

GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

Completed·QQueen Mary University of London·Phase 2·NCT06309732·36 enrolled

Primary Peritoneal Cavity Cancer1 trial

Docetaxel and Carboplatin in Treating Patients With Relapsed Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cavity Cancer

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00217568

Urothelial Carcinoma1 trial

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

Completed·—·Phase 2·NCT00808639·39 enrolled

Biosimilarity1 trial

Comparison of the Pharmacokinetic and Pharmacodynamic Biosimilarity of CHS-1701 (Coherus Pegfilgrastim) With Neulasta® (Pegfilgrastim)

Completed·CCoherus Oncology, Inc.·Phase 1·NCT02385851·116 enrolled

Tics1 trial

Pharmacokinetics and Pharmacodynamics Comparison Study Between Two Pegfilgrastim Formulations

Completed·EEurofarma Laboratorios S.A.·Phase 1·NCT02589301·100 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00280787·24 enrolled

Acute Myeloid Leukaemia (AML)1 trial

Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

Completed· Amgen logo

Amgen·Phase 2·NCT00114764·84 enrolled

Stem Cells1 trial

KRN125 for Mobilization of Hematopoietic Stem Cells

Completed· Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.·Phase 2·NCT03993639·35 enrolled

Solid Tumors1 trial

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Terminated·MMayo Clinic·Phase 1·NCT02650635·4 enrolled

Hematologic Malignancies1 trial

Feasibility and Cost Analysis of PBSC Mobilization Using Pegfilgrastim in Hematologic Malignancies

Terminated·—·N/A·NCT00689884·7 enrolled

Prostate Cancer1 trial

Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer

Completed·RRahul Aggarwal·Phase 1·NCT01594918·25 enrolled

ESS1 trial

Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With Neulasta

Completed·CCoherus Oncology, Inc.·Phase 1·NCT02650973·122 enrolled

Neuroblastoma1 trial

Decitabine, Doxorubicin, and Cyclophosphamide in Treating Children With Relapsed or Refractory Solid Tumors or Neuroblastoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00075634·21 enrolled

Carcinosarcoma1 trial

Carboplatin, Paclitaxel, and Pegfilgrastim in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Fallopian Tube, Primary Peritoneal, or Carcinosarcoma Cancer

Completed·GGynecologic Oncology Group·Phase 1·NCT00352300·43 enrolled

Acute Myeloid Leukemia1 trial

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·UUniversity of Ulm·Phase 2/3·NCT00151242·920 enrolled

Metastatic Prostate Cancer1 trial

A Phase I/II Study of Azacitidine, Docetaxel, and Prednisone for Metastatic Prostate Cancer Patients

Terminated·UUniversity of Miami·Phase 1/2·NCT00503984·22 enrolled

Prostate1 trial

Pazopanib, Docetaxel, Prednisone Prostate

Completed·—·Phase 1·NCT01385228·36 enrolled

Urothelial Cancer1 trial

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Withdrawn·UUniversity of Southern California·Phase 2·NCT01639521

Urinary Tract Cancer1 trial

Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer

Completed·EECOG-ACRIN Cancer Research Group·Phase 2·NCT02412670·36 enrolled

High Grade Glioma1 trial

PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (GLOBOTRK)

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT06528691·52 enrolled

Myelodysplastic Syndromes1 trial

A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML

Recruiting·MM.D. Anderson Cancer Center·Preclinical·NCT03214562·116 enrolled

Renal Pelvis and Ureter Urothelial Carcinoma1 trial

A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Recruiting·NNational Cancer Institute (NCI)·Preclinical·NCT04628767·131 enrolled

Stage III1 trial

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT03907488·994 enrolled

Hodgkin Lymphoma, Adult1 trial

Pembrolizumab and GVD With ctDNA-guided Consolidation in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma: A Multicenter Phase 2 Study of the University of California Hematologic Malignancies Consortium

Recruiting·MMichael Spinner, MD·Phase 2·NCT07021989·38 enrolled

Infiltrating Bladder Urothelial Carcinoma1 trial

A Phase II Study of Gemcitabine Plus Cisplatin Chemotherapy in Patients With Muscle-invasive Bladder Cancer With Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 2·NCT03609216·237 enrolled

Primary Mediastinal Lymphoma1 trial

Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active, not recruiting·NNational Research Center for Hematology, Russia·Phase 3·NCT06188676·60 enrolled

Mediastinal Large B-cell Lymphoma1 trial

A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT04759586·244 enrolled

B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative1 trial

Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) ± Rituximab + Recombinant Erwinia Asparaginase (JZP458; Rylaze®) for the Treatment of Newly-Diagnosed Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Lymphoma/Leukemia

Suspended·UUniversity of Washington·Phase 2·NCT06738368·30 enrolled

Central Nervous System Nongerminomatous Germ Cell Tumor1 trial

A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Recruiting·CChildren's Oncology Group·Phase 2·NCT04684368·160 enrolled

DLBCL - Diffuse Large B Cell Lymphoma1 trial

ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial

Recruiting·SStichting Hemato-Oncologie voor Volwassenen Nederland·Phase 3·NCT06220032·324 enrolled

Metastatic Castration-Resistant Prostate Cancer1 trial

A Phase 1b/2 Study of FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer

Active, not recruiting·RRahul Aggarwal·Preclinical·NCT05011188·44 enrolled

Medulloblastoma1 trial

SJiMB21: Phase 2 Study of Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT05535166·130 enrolled

Lung Adenocarcinoma1 trial

A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT00334815·29 enrolled

Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1 trial

Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03147612·22 enrolled

B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL11 trial

Phase II Study of Dose-Adjusted EPOCH ± Rituximab + Ponatinib for Adults With Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Recruiting·UUniversity of Washington·Phase 2·NCT07224100·33 enrolled

Unspecified2 trials

NOLAN: Naproxen or Loratadine and Neulasta

Completed· Amgen logo

Amgen·Phase 2·NCT01712009·600 enrolled

Pegfilgrastim PBPC Mobilization Study

Completed· Amgen logo

Amgen·Phase 2·NCT00066092·41 enrolled

Sources

References

[1]
ClinicalTrials.gov — 206 trial records for Pegfilgrastim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pegfilgrastim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pegfilgrastim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Amgen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Granulocyte Colony Stimulating Factor Receptor Agonist[2]
Modality: Protein / enzyme[2]
Highest Phase: Phase 3[1]
Company: Amgen